See more : Maccura Biotechnology Co.Ltd (300463.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Cannara Biotech Inc. (LOVFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cannara Biotech Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Indo-City Infotech Limited (INDOCITY.BO) Income Statement Analysis – Financial Results
- AIB Group plc (AIBGY) Income Statement Analysis – Financial Results
- Xinjiang Goldwind Science & Technology Co., Ltd. (002202.SZ) Income Statement Analysis – Financial Results
- African Discovery Group, Inc. (AFDG) Income Statement Analysis – Financial Results
- Rimbaco Group Global Limited (1953.HK) Income Statement Analysis – Financial Results
Cannara Biotech Inc. (LOVFF)
About Cannara Biotech Inc.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 81.75M | 57.26M | 35.84M | 17.02M | 2.55M | 2.10M | 432.64K |
| Cost of Revenue | 51.96M | 30.03M | 18.51M | 6.72M | 1.33M | 403.90K | 273.58K |
| Gross Profit | 29.79M | 27.23M | 17.33M | 10.30M | 1.22M | 1.69M | 159.06K |
| Gross Profit Ratio | 36.44% | 47.56% | 48.36% | 60.50% | 48.00% | 80.74% | 36.76% |
| Research & Development | 1.12M | 1.03M | 1.26M | 1.91M | 2.60M | 0.00 | 0.00 |
| General & Administrative | 12.97M | 10.61M | 8.59M | 6.16M | 8.06M | 10.58M | 1.60M |
| Selling & Marketing | 6.68M | 2.91M | 1.44M | 1.14M | 904.66K | 765.93K | 271.35K |
| SG&A | 19.65M | 13.52M | 10.03M | 7.30M | 8.97M | 11.35M | 1.87M |
| Other Expenses | -1.06M | 792.03K | 0.00 | 24.44K | 25.89K | 0.00 | 0.00 |
| Operating Expenses | 19.71M | 15.34M | 12.36M | 10.00M | 13.15M | 11.92M | 1.98M |
| Cost & Expenses | 71.67M | 45.37M | 30.87M | 16.72M | 14.48M | 12.32M | 2.25M |
| Interest Income | 178.96K | 0.00 | 92.69K | 52.79K | 265.77K | 679.62K | 27.09K |
| Interest Expense | 4.33M | 4.29M | 1.92M | 1.57M | 1.33M | 1.51M | 319.93K |
| Depreciation & Amortization | 6.35M | 4.94M | 3.92M | 3.03M | 2.58M | 566.33K | 109.68K |
| EBITDA | 15.16M | 15.77M | 8.40M | 3.06M | -9.19M | -10.89M | -1.68M |
| EBITDA Ratio | 18.55% | 27.54% | 21.18% | 18.91% | -357.47% | -428.81% | -389.08% |
| Operating Income | 10.08M | 11.89M | 4.94M | 257.28K | -11.95M | -10.22M | -1.82M |
| Operating Income Ratio | 12.33% | 20.76% | 13.78% | 1.51% | -468.56% | -487.52% | -420.01% |
| Total Other Income/Expenses | -5.59M | -4.94M | -2.64M | -1.79M | -1.14M | -2.75M | -295.77K |
| Income Before Tax | 4.48M | 6.95M | 2.31M | -1.53M | -13.09M | -12.97M | -2.11M |
| Income Before Tax Ratio | 5.49% | 12.13% | 6.43% | -8.98% | -513.33% | -618.60% | -488.38% |
| Income Tax Expense | -1.95M | 0.00 | 1.92M | 1.57M | 713.90K | 855.93K | 24.17K |
| Net Income | 6.44M | 6.95M | 2.31M | -1.53M | -12.48M | -12.32M | -2.11M |
| Net Income Ratio | 7.88% | 12.13% | 6.43% | -8.98% | -489.35% | -587.28% | -488.38% |
| EPS | 0.00 | 0.08 | 0.03 | -0.02 | -0.17 | -0.17 | -0.03 |
| EPS Diluted | 0.00 | 0.08 | 0.03 | -0.02 | -0.17 | -0.17 | -0.03 |
| Weighted Avg Shares Out | 0.00 | 89.30M | 87.67M | 76.52M | 71.33M | 70.68M | 69.38M |
| Weighted Avg Shares Out (Dil) | 0.00 | 89.30M | 87.84M | 76.52M | 71.33M | 70.68M | 69.38M |
Cannara Biotech Receives Sales Licence from Health Canada
Cannara Biotech Inc. (CSE: LOVE) announces Year-End and Q4 2020 Results
Source: https://incomestatements.info
Category: Stock Reports